Healthcare Industry News:  OXINIUM 

Devices Orthopaedic

 News Release - August 30, 2006

Smith & Nephew Launches the EMPERION(TM) Modular Hip System

MEMPHIS, Tenn., Aug. 30 (HSMN NewsFeed) -- Smith & Nephew's (NYSE: SNN ; LSE: SN ) Orthopaedic Reconstruction division today announced the launch of the EMPERION(TM) Modular Hip System for primary and revision total hip arthroplasty. This system will be available in the United States, Europe, Australia and Canada.

A modular hip system offers optimal sizing of the joint implants and allows for greater flexibility to more accurately match the implant to a patient's anatomy compared to other systems. The EMPERION implant uses a titanium press-fit stem. It is the only modular hip system that can be used with Smith & Nephew's proprietary OXINIUM(TM) femoral heads.

The EMPERION system builds on the clinical success of older implant designs while providing surgeons with enhanced performance during surgery. Easy to use instrumentation and color-coding improves efficiency during the procedure. Innovative features of the implant, such as the Smith & Nephew circulotrapezoidal neck design allows for a greater range of motion and the bullet tip shape of the stem reduces thigh pain and makes insertion of the device easier.

"Smith & Nephew's EMPERION Modular Hip System offers surgeons greater flexibility to adapt a total hip replacement to their patients' specific needs, potentially reducing post-operative complications," said Scott Flora, president of Smith & Nephew Orthopaedic Reconstruction. "The EMPERION system complements our existing primary and revision hip portfolio, and reflects Smith & Nephew's commitment to providing true innovation to benefit surgeons and patients."

"The EMPERION system provides me the versatility to reconstruct the hip joint in a simple, straight-forward manner, while still employing less invasive or tissue-preserving surgical techniques," said Dr. Bertrand Kaper with Yavapai Medical Center in Prescott, Arizona. "It takes the evolution of hip replacement surgery to the next level of clinical success."

About OXINIUM(TM)

OXINIUM material is a unique and advanced bearing product technology. It is created through a proprietary manufacturing process that enables zirconium alloy to absorb oxygen and transform to a ceramic on the surface, resulting in a material that incorporates the best features of ceramic and metal while avoiding the limitations associated with either material. OXINIUM material is a revolutionary technology used in the production of components of knee and hip implants that exhibits superior performance characteristics due to its hardness, low-friction and resistance to roughening and abrasion.

The concept of using oxidized zirconium as a joint replacement material was developed by the many individuals within Smith & Nephew's Orthopaedic Research, Development, and Manufacturing groups. The first oxidized zirconium component was implanted in 1995. Since then, over 100,000 hip and knee components have been implanted with remarkable success.

(TM) Trademark of Smith & Nephew

About Us

Smith & Nephew is a global medical technology business, specializing in, Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies. Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has more than 8,500 employees and operates in 33 countries around the world and generated sales of nearly $2.6 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim," "plan," "intend," "anticipate," "well-placed," "believe," "estimate," "expect," "target," "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Source: Smith & Nephew

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.